Glucose-dependent Insulinotropic Polypeptide Receptor: Difference between revisions
Michal Harel (talk | contribs) No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
< | <StructureSection load='2qkh' size='350' side='right' caption=Glucose-dependant insulinotropic polypeptide receptor (grey) complex with hormone GIP (green), methyl-cyclo-hepta-amylose and tartaric acid , [[2qkh]]' scene=''> | ||
[[Image:F3.large.jpg|thumb|300px|left|GIP-induced Pathway.<ref>PMID:12475913</ref>]] | [[Image:F3.large.jpg|thumb|300px|left|GIP-induced Pathway.<ref>PMID:12475913</ref>]] | ||
| Line 47: | Line 47: | ||
===Ongoing Research=== | ===Ongoing Research=== | ||
The significance of this receptor makes it a prime target for [[Diabetes]] research. Incretins are a class of biological molecules that act like gastrointestinal hormones. One such example is glucagon-like peptide-1 (GLP-1), which works with GIP to regulate the body's insulin levels. Synthetic versions of this peptide hormone have been made to treat people with type-2 diabetes. It works by stimulating GIP production as well as insulin secretion causing the body to properly regulate its blood glucose levels like someone without diabetes. The benefit of synthetic GLP-1 is that it is not protein and so would not be degraded as easily therefore prolonging the benefits of the drug. One such example is Byetta<ref>"Byetta." BYETTA (exenatide) Injection | Welcome to BYETTA.com. Amylin Pharmaceuticals, Inc., 2011. Web. 02 Dec. 2011. <http://www.byetta.com/Pages/index.aspx></ref>. | The significance of this receptor makes it a prime target for [[Diabetes]] research. Incretins are a class of biological molecules that act like gastrointestinal hormones. One such example is glucagon-like peptide-1 (GLP-1), which works with GIP to regulate the body's insulin levels. Synthetic versions of this peptide hormone have been made to treat people with type-2 diabetes. It works by stimulating GIP production as well as insulin secretion causing the body to properly regulate its blood glucose levels like someone without diabetes. The benefit of synthetic GLP-1 is that it is not protein and so would not be degraded as easily therefore prolonging the benefits of the drug. One such example is Byetta<ref>"Byetta." BYETTA (exenatide) Injection | Welcome to BYETTA.com. Amylin Pharmaceuticals, Inc., 2011. Web. 02 Dec. 2011. <http://www.byetta.com/Pages/index.aspx></ref>. | ||
</StructureSection> | |||
===3D structures of GIPR=== | ===3D structures of GIPR=== | ||